Loading...

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Hematol
Main Authors: Yilmaz, Musa, Richard, Samantha, Jabbour, Elias
Format: Artigo
Language:Inglês
Published: SAGE Publications 2015
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/
https://ncbi.nlm.nih.gov/pubmed/26425338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715
Tags: Add Tag
No Tags, Be the first to tag this record!